newsfilter
← Latest News
Business Wire·

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren's syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A and BAFF in a